水痘-带状疱疹疫苗的使用现状及研究进展  

Application and progress in development of varicella-zoster virus

作　　者：吴根鹏[1] 朱为[1] 

机构地区：[1]上海生物制品研究所有限责任公司,上海200052

出　　处：《中国生物制品学杂志》2016年第3期323-328,332,共7页Chinese Journal of Biologicals

摘　　要：水痘-带状疱疹病毒(varicella-zoster virus,VZV)可引起水痘和带状疱疹(herpes zoster,HZ),具有较高的传染性和发病率。目前V-Oka减毒株是WHO推荐的唯一可用于疫苗生产的毒株。自上市以来,水痘疫苗证实了其良好的有效性和安全性。水痘-带状疱疹疫苗的开发及应用受到国内外生物制药企业的广泛重视。本文现就水痘和HZ的流行病学、疫苗的发展和现状作一综述。Varicella-zoster virus（VZV）is the pathogen of varicella（chicken pox）and herpes zoster（shingles,HZ）, with a high infectivity and morbidity. VZV-Oka strain is the only strain used for vaccine production recommended by the WHO.The effectiveness and safety of varicella vaccine have been confirmed in post-marketing application. Meanwhile, HZ vaccines are under development by many pharmaceutical companies. This paper reviews the epidemiology of VZV and development of vaccines.

关 键 词：水痘-带状疱疹病毒 疫苗 

分 类 号：R373.12[医药卫生—病原生物学] R392-33[医药卫生—基础医学]